Artemis Medicare Analyst Review 2027: Record Hospital Margin, Flat Profit and 250 New Beds Ahead
- November 20, 2026
- Posted by: Kunal Singla
- Category: Market
Artemis Medicare Services Stock Snapshot (19 Nov 2026)
- Current Market Price (CMP): ₹339.20
- 52-Week High / Low: ₹378.80 / ₹203.35
- Market Capitalisation: ₹5,370 crore
- P/E Ratio vs Industry P/E: 46.7 vs 63.7
- Latest Quarter (Q2 FY27) Revenue: ₹311 crore
- Latest Quarter (Q2 FY27) Net Profit: About ₹31.1 crore
Quick Answer: The Artemis Medicare analyst review 2027 finds no fresh named brokerage target after the Q2 FY27 results. Consolidated revenue from operations rose 13.2% to ₹311 crore and adjusted operational EBITDA margin reached 23.3%, but net profit was nearly flat at about ₹31.1 crore. The stock closed at ₹339.20 on 19 November 2026, about 10% below its 52-week high, at about 47 times trailing earnings, which frames any Artemis Medicare share price target 2027 discussion.
The Artemis Medicare analyst review 2027 covers Artemis Medicare Services, which runs the Artemis Hospital in Gurugram and a growing network of smaller centres in north India. The company is part of the Onkar Kanwar group. Readers searching for an Artemis Medicare share price target 2027 want to know whether bed expansion and higher margins can justify the current valuation.
Artemis Medicare closed at ₹339.20 on 19 November 2026, about 10% below its 52-week high of ₹378.80 and about 67% above its low of ₹203.35. This Artemis Medicare analyst review 2027 explains the quarter and what shapes the Artemis Medicare stock outlook 2027.
Click Here – Get Free Investment Predictions
What Analysts Say in the Artemis Medicare Analyst Review 2027
| Brokerage | Rating | Target Price | Date |
|---|---|---|---|
| No fresh named coverage found | Not available | Not available | As of November 2026 |
A handful of analysts track the company, but we could not verify a named brokerage report with a target price after the Q2 FY27 results. Institutional holding is about 14%, mostly foreign investors.
Without published targets, this Artemis Medicare analyst review 2027 relies on hospital margins, occupancy, bed expansion and valuation compared with larger listed hospital chains.
Q2 FY27 Results in the Artemis Medicare Analyst Review 2027
| Metric | Q2 FY27 | Q2 FY26 | Change |
|---|---|---|---|
| Revenue from operations | ₹311 crore | About ₹275 crore | Up 13.2% |
| Adjusted operational EBITDA margin | 23.3% | Lower | Improved |
| Gurgaon hospital EBITDA margin | 23.8% | Lower | Highest ever |
| Net profit | About ₹31.1 crore | About ₹30.0 crore | Up about 4% |
| Gurgaon hospital occupancy | 68% | Not compared | Steady |
Revenue growth came from cardiac sciences, oncology, neurosciences, orthopaedics and transplants. H1 FY27 adjusted operational EBITDA margin was 22.4%, so Q2 marked an improvement within the year.
Net profit grew far slower than revenue, held back by costs below the operating line, such as depreciation and interest, as the company adds new centres. In this Artemis Medicare analyst review 2027, the gap between rising operating margin and flat net profit is the key point for investors.
On a sequential basis, revenue also rose from the Q1 FY27 level, while net profit stayed close to the Q1 level of about ₹31.4 crore. That flat profit trend across both quarters of FY27 suggests the business is in an investment phase, where higher spending on people, equipment and new sites is running ahead of the earnings they will eventually bring.
How Artemis Medicare Makes Money
Artemis earns revenue from patients treated at its hospitals and centres.
- Flagship hospital: a large multi-speciality hospital in Gurugram, the main earnings engine.
- Specialities: cardiac, cancer, neuro, orthopaedic and organ transplant care.
- International patients: overseas patients who pay higher rates per treatment.
- Smaller centres: satellite hospitals and clinics in Delhi NCR and nearby states.
FY26 revenue was about ₹1,111 crore with net profit of about ₹104 crore, after ₹970 crore and ₹82 crore in FY25 and ₹886 crore and ₹49 crore in FY24. Profit has roughly doubled in two years, which supports this Artemis Medicare analyst review 2027.
The next big step is Tower 4 at the Gurugram campus, which is expected to add about 250 beds by the second half of FY28. New beds usually lower margins at first because they start with low occupancy, then lift earnings as they fill up.
Debt to equity of about 0.33 is manageable, and operating cash flow was about ₹132 crore in FY26. Smaller hospital stocks tend to move more sharply than the broader Nifty Smallcap 100 index, and Artemis has risen about 67% from its yearly low.
Hospital earnings depend on average revenue per occupied bed as well as occupancy. A richer mix of complex procedures, such as transplants and cancer surgery, raises revenue per bed, while a higher share of insurance and government scheme patients can lower it. With occupancy at 68%, the flagship hospital still has some room to fill existing beds before Tower 4 opens.
Growth Triggers in the Artemis Medicare Analyst Review 2027
- Record margin: Gurgaon hospital EBITDA margin of 23.8%.
- Bed expansion: Tower 4 to add about 250 beds by H2 FY28.
- Speciality mix: high-value cardiac, cancer and transplant care.
- Medical tourism: steady flow of international patients.
- Two-year profit growth: FY26 profit about double FY24, relevant to any Artemis Medicare share price target 2027 view.
Key Risks in the Artemis Medicare Analyst Review 2027
- Flat profit: Q2 net profit up only about 4%.
- Valuation: about 47 times trailing earnings.
- Expansion costs: new beds and centres weigh on early returns.
- Single-site reliance: one hospital drives most earnings.
- Competition: large chains are expanding in Delhi NCR, a key point in the Artemis Medicare analyst review 2027.
Compare Artemis Medicare With Other Hospital Stocks on the Univest Screener
Artemis Medicare Analyst Review 2027: Stock at a Glance
| Metric | Value |
|---|---|
| Share Price (19 Nov 2026) | ₹339.20 |
| 52-Week High / Low | ₹378.80 / ₹203.35 |
| Market Capitalisation | About ₹5,370 crore |
| P/E (TTM) | About 46.7 |
| Industry P/E | About 63.7 |
| Return on Equity | About 11.6% |
| Debt to Equity | 0.33 |
| FY26 Revenue / Net Profit | About ₹1,111 crore / ₹104 crore |
The P/E of about 47 is below the hospital industry level of about 64, where larger chains trade at high multiples. In this Artemis Medicare analyst review 2027, the stock looks less stretched than big peers but still prices in growth from new beds.
Shareholding Trend
| Holder | Nov 2025 | Sep 2026 | Change |
|---|---|---|---|
| Promoters | 58.43% | 58.39% | Down 0.04 pts |
| Foreign Investors (FII) | 12.48% | 12.46% | Down 0.02 pts |
| Domestic Institutions (DII) | 3.35% | 1.91% | Down 1.44 pts |
| Public | 25.75% | 27.24% | Up 1.49 pts |
Constructive Finance holds 58.38%, almost all of the promoter stake. Foreign holding was stable while domestic institutions trimmed, which the Artemis Medicare analyst review 2027 reads as limited local fund interest in the stock.
What to Watch After the Artemis Medicare Analyst Review 2027
- Margins: whether operating margin stays above 23%.
- Net profit: whether it starts to grow with revenue.
- Tower 4: construction progress and opening timeline.
- Occupancy: any rise above 68% at the flagship hospital.
- Coverage: any named research that sets an Artemis Medicare share price target 2027.
Final Word on the Artemis Medicare Analyst Review 2027
The Artemis Medicare analyst review 2027 shows steady revenue growth, a record margin at the flagship hospital and a clear expansion plan. Net profit was flat in Q2, and the stock trades at a high multiple.
The Artemis Medicare stock outlook 2027 depends on profit catching up with margins and on the Tower 4 rollout. Univest does not give a buy or sell call.
Disclaimer: This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions
What does the Artemis Medicare analyst review 2027 show?
It shows steady revenue growth with flat profit. Q2 FY27 consolidated revenue from operations rose 13.2% to ₹311 crore and adjusted operational EBITDA margin was 23.3%. Net profit was about ₹31.1 crore, up about 4%.
Is there an Artemis Medicare share price target 2027 from brokerages?
We could not verify a named brokerage target after the Q2 FY27 results. The stock closed at ₹339.20 on 19 November 2026, about 10% below its 52-week high of ₹378.80. Results and valuation are the main reference points.
Why was Artemis Medicare’s profit flat in Q2 FY27?
Costs below the operating line, such as depreciation and interest, absorbed most of the gain in operating profit as new centres were added. Revenue rose 13.2% while net profit rose only about 4%. The flagship hospital still posted a record EBITDA margin of 23.8%.
What expansion is Artemis Medicare planning?
Tower 4 at the Gurugram campus is expected to add about 250 beds by the second half of FY28. The company is also adding smaller centres in north India. New beds may weigh on margins at first until occupancy builds.
Is Artemis Medicare stock overvalued based on the Artemis Medicare analyst review 2027?
The stock trades at about 47 times trailing earnings, below the hospital industry P/E of about 64. Return on equity is about 11.6%. The valuation assumes profit growth returns as new beds fill.
Who owns Artemis Medicare?
Promoters hold 58.39%, almost all through Constructive Finance. Foreign investors hold 12.46% and domestic institutions 1.91%. Public shareholders hold 27.24%.
What should investors watch after the Artemis Medicare analyst review 2027?
Watch whether margin stays above 23% and whether net profit starts to grow with revenue. Track Tower 4 construction and occupancy at the flagship hospital. Any named research coverage would also add a reference point.